By updating the terminology, we aim to set a cleaner, more responsible standard for the industry
The unexpectedly profound weight loss observed in diabetes trials drove development of a higher-dose formulation Wegovy (up to 2.4 mg weekly) which received FDA approval in 2021 and EMA approval in 2023 specifically for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity
-
The peptide works through several mechanisms: it upregulates growth factor expression (particularly VEGF), promotes angiogenesis (the formation of new blood vessels at injury sites) [5,12] , modulates the nitric oxide system, and supports the FAK-paxillin pathway, which governs cell migration to damaged tissue
During these consultations, we take the time to understand your aesthetic goals, evaluate your suitability for the procedure, and explain every step of the process